Literature DB >> 17229747

Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.

S Vulliemoz1, G Vanini, A Truffert, C Chizzolini, M Seeck.   

Abstract

Anti-glutamic acid decarboxylase (GAD) antibodies are described in stiff-person syndrome and also in other neurological syndromes, including cerebellar ataxia and epilepsy. This paper reports the case of a patient who had chronic focal epilepsy, upbeat nystagmus and cerebellar ataxia, associated with a polyautoimmune response including anti-GAD antibodies. Both gait and nystagmus improved markedly after immunosuppressive treatment with corticosteroids and azathioprine. After the introduction of benzodiazepines, previously refractory seizures were completely controlled. Anti-GAD antibodies should be actively sought out in pharmacoresistant epilepsy, particularly if other neurological abnormalities are present. Combined treatment with immunosuppressants and gammahydroxybutyric acidergic agents may be highly effective.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17229747      PMCID: PMC2077657          DOI: 10.1136/jnnp.2006.089268

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies.

Authors:  B Giometto; P Nicolao; M Macucci; B Tavolato; R Foxon; G F Bottazzo
Journal:  Lancet       Date:  1998-08-08       Impact factor: 79.321

2.  Anti-GAD antibodies and periodic alternating nystagmus.

Authors:  Caroline Tilikete; Alain Vighetto; Paul Trouillas; Jérome Honnorat
Journal:  Arch Neurol       Date:  2005-08

3.  The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies.

Authors:  Marinos C Dalakas
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

4.  Antigenic differences between neurological and diabetic patients with anti-glutamic acid decarboxylase antibodies.

Authors:  M Vianello; G Keir; B Giometto; C Betterle; B Tavolato; E J Thompson
Journal:  Eur J Neurol       Date:  2005-04       Impact factor: 6.089

5.  Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome.

Authors:  M Solimena; F Folli; R Aparisi; G Pozza; P De Camilli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

6.  Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase.

Authors:  S F Kash; R S Johnson; L H Tecott; J L Noebels; R D Mayfield; D Hanahan; S Baekkeskov
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

7.  Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome.

Authors:  K Dinkel; H M Meinck; K M Jury; W Karges; W Richter
Journal:  Ann Neurol       Date:  1998-08       Impact factor: 10.422

8.  Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition.

Authors:  K Daw; N Ujihara; M Atkinson; A C Powers
Journal:  J Immunol       Date:  1996-01-15       Impact factor: 5.422

9.  Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity.

Authors:  R A Barker; T Revesz; M Thom; C D Marsden; P Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

10.  Homozygosity for a missense mutation in the 67 kDa isoform of glutamate decarboxylase in a family with autosomal recessive spastic cerebral palsy: parallels with Stiff-Person Syndrome and other movement disorders.

Authors:  Clare N Lynex; Ian M Carr; Jack P Leek; Rajgopal Achuthan; Simon Mitchell; Eamonn R Maher; C Geoffrey Woods; David T Bonthon; Alex F Markham
Journal:  BMC Neurol       Date:  2004-11-30       Impact factor: 2.474

View more
  17 in total

Review 1.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

2.  Anti-GAD antibody ocular flutter: expanding the spectrum of autoimmune ocular motor disorders.

Authors:  Raffaele Dubbioso; Vincenzo Marcelli; Fiore Manganelli; Rosa Iodice; Marcello Esposito; Lucio Santoro
Journal:  J Neurol       Date:  2013-09-22       Impact factor: 4.849

3.  New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin.

Authors:  Michael Marnane; Aangela Vincent; Michael Hutchinson
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

Review 4.  Ataxia.

Authors:  Umar Akbar; Tetsuo Ashizawa
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

5.  Anti-GAD Antibody, Seizures, Cerebellar Ataxias and Vitiligo: A Diagnostic Challenge.

Authors:  Hazael Flores-Cantu; Carlos R Camara-Lemarroy; Hector J Calderon-Hernandez; Maria A Zapata-Rivera; Jesus Z Villareal-Perez; Hector J Villareal-Velazquez
Journal:  Cerebellum       Date:  2015-06       Impact factor: 3.847

6.  Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.

Authors:  Timotej Petrijan; Marija Menih
Journal:  Cerebellum       Date:  2017-08       Impact factor: 3.847

7.  Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.

Authors:  Helena Ariño; Nuria Gresa-Arribas; Yolanda Blanco; Eugenia Martínez-Hernández; Lidia Sabater; Mar Petit-Pedrol; Idoia Rouco; Luis Bataller; Josep O Dalmau; Albert Saiz; Francesc Graus
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

8.  Stiff person syndrome: advances in pathogenesis and therapeutic interventions.

Authors:  Marinos C Dalakas
Journal:  Curr Treat Options Neurol       Date:  2009-03       Impact factor: 3.598

Review 9.  Advances in the pathogenesis and treatment of patients with stiff person syndrome.

Authors:  Marinos C Dalakas
Journal:  Curr Neurol Neurosci Rep       Date:  2008-01       Impact factor: 5.081

10.  Epilepsia partialis continua in type 1 diabetes: evolution into epileptic encephalopathy with continuous spike-waves during slow sleep.

Authors:  Maria Giuseppina Baglietto; Maria Margherita Mancardi; Alessandro Giannattasio; Nicola Minuto; Andrea Rossi; Giuseppe Capovilla; Edvige Veneselli; Renata Lorini; Giuseppe d'Annunzio
Journal:  Neurol Sci       Date:  2009-08-15       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.